EN DE
Watch DiaMedica Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

DiaMedica Therapeutics Inc (DMAC) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of DiaMedica Therapeutics Inc stock $4.94, price $8.33, that is 40.7% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA25253X2077

DT DiaMedica Therapeutics Inc logo Thin data Nov 15, 2026

DiaMedica Therapeutics Inc

DMAC · US

Far too expensive (fair value 41% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Fair value $4.94 · Strongly overvalued 
Quality 32/100 
Weak Growth 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch DiaMedica Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.77 $1.13 Fair Value $4.94 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $1.13 – $10.77 · fair‑value band $3.70 – $6.17 · the $8.33 price screens above the $4.94 fair value. As of Nov 15, 2026.

Follow DiaMedica Therapeutics in your weekly email

Every Wednesday you see whether DiaMedica Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.

Show moreShow less

Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.

DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Stock analysis

DiaMedica Therapeutics Inc (DMAC) currently trades at $8.33, while our estimate is $4.94, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.70 (bear) to $6.17 (bull), the price of $8.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

DiaMedica Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$32.8M in FY2025.

Key figures

Market cap $449M Small · EPS (TTM) $−0.7500 · Return on equity −100% · Return on assets (EBIT) −44.7% (5-year average) · Free cash flow −$29.1M · Net cash $15.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, DMAC screens richer than that median.

Fair Value

Bear $3.70 Fair Value $4.94 Bull $6.17
Price $8.33 · Downside -40.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 47
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 35
How calm the share price moves, does not count
Price momentum 87
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 74
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyAb Trill10% owner1,061,277 shares at $7.19$7.6MNov 25, 2025

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,781.0% (2004) → −1,352.2% (2018)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DMAC screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare DiaMedica Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 0/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −40.7% · Bottom 25%
Profitability
Return on assets −53.4% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.00× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs DMAC
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs DMAC
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs DMAC
argenx SE ARGX $950.95 $908.40 −4% vs DMAC
CSL Limited CSL A$199.55 A$186.49 −7% vs DMAC
Moderna, Inc MRNA $215.27 $135.64 −37% vs DMAC
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs DMAC
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs DMAC
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs DMAC
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs DMAC

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DiaMedica Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DiaMedica Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/DMAC

Frequently asked questions

Is DiaMedica Therapeutics Inc (DMAC) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $4.94 versus a price of $8.33, about 41% lower (overvalued).
What is the fair value of DMAC?
Our estimate for DiaMedica Therapeutics Inc is $4.94 (as of Nov 15, 2026), built from audited fundamentals. The current price: $8.33.
What is the quality score of DMAC?
DiaMedica Therapeutics Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DiaMedica Therapeutics Inc (DMAC)?
Our calculated price target is the estimate of $4.94 (as of Nov 15, 2026). Cautious scenario $3.70, optimistic scenario $6.17. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the DiaMedica Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $4.94, about 41% lower versus a price of $8.33 (overvalued). Cautious scenario $3.70, optimistic scenario $6.17. The calculation is refreshed regularly with new filings.
What is the intrinsic value of DiaMedica Therapeutics Inc (DMAC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DiaMedica Therapeutics Inc it is $4.94 per share (as of Nov 15, 2026), against a price of $8.33.
Is DiaMedica Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, DMAC trades above its calculated fair value: price $8.33, fair value $4.94, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DMAC?
No. The price is what the market pays today ($8.33); the fair value is what the company's own numbers justify ($4.94). For DiaMedica Therapeutics Inc the two are $3.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is DiaMedica Therapeutics Inc worth?
The market values DiaMedica Therapeutics Inc at about $449M (market capitalisation, as of Nov 15, 2026). Per share that is $8.33; our models calculate a fair value of $4.94 per share.
What do the bullish and bearish scenarios say about DMAC?
Our models span a range for DiaMedica Therapeutics Inc: cautious scenario $3.70, base $4.94, optimistic $6.17 per share (as of Nov 15, 2026, price $8.33). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DiaMedica Therapeutics Inc (DMAC)?
Balance-sheet figures for DiaMedica Therapeutics Inc (as of Nov 15, 2026): return on equity −100.2%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is DMAC from its 52-week high?
DiaMedica Therapeutics Inc trades at $8.33, about 23% below its 52-week high of $10.77 and 56% above the low of $5.33 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $4.94 is for.
Which stocks are comparable to DiaMedica Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DiaMedica Therapeutics Inc stock attractive at the current price?
The data as of Nov 15, 2026: price $8.33, calculated fair value $4.94 (−41%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. DiaMedica Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DiaMedica Therapeutics Inc (DMAC)?
The closing price on Nov 16, 2026 was $8.33. Our estimate is $4.94, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DiaMedica Therapeutics Inc right now?
The price sits above even our optimistic bull case ($6.17). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of DiaMedica Therapeutics Inc

How large is the market capitalisation of DiaMedica Therapeutics Inc (DMAC)?
The market capitalisation of DiaMedica Therapeutics Inc is $449M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of DiaMedica Therapeutics Inc (DMAC)?
Earnings per share at DiaMedica Therapeutics Inc are $−0.7500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of DiaMedica Therapeutics Inc (DMAC)?
The return on equity (ROE) of DiaMedica Therapeutics Inc is −100% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DiaMedica Therapeutics Inc (DMAC)?
On an EBIT basis the return on assets of DiaMedica Therapeutics Inc is −44.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does DiaMedica Therapeutics Inc (DMAC) generate?
The free cash flow of DiaMedica Therapeutics Inc is −$29.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does DiaMedica Therapeutics Inc (DMAC) hold?
DiaMedica Therapeutics Inc holds more cash than debt, $15.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch DiaMedica Therapeutics Inc in the live analysis

One click puts DiaMedica Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.